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background:  No data exist on high platelet reactivity (HPR) rate following standard clopidogrel treatment in patients with ST elevation myocardial 
infarction (STEMI) post thrombolysis and ticagrelor’s pharmacodynamic effect in these patients.
methods: This was a prospective, 2-center, randomized study of parallel design. Patients with STEMI, who present HPR (defined as PRU ≥208) 3 
to 48 hours post thrombolysis and standard clopidogrel treatment [300mg loading dose (LD), 75mg maintenance dose (MD)] were randomized pre 
coronary angiography to ticagrelor 180mg LD, 90mg bid MD or clopidogrel 600mg LD, 150mg MD. Platelet reactivity (PR) assessment was performed 
at randomization (Hour 0) and at 2, 24 hours after randomization, as well as pre-discharge, using the VerifyNow assay, in platelet reactivity units 
(PRU). Primary endpoint was PR at Hour 2 between groups.
results: Out of 36 screened patients, 23(63.9%) presented HPR (87% men, 21.7% diabetics) and were all randomized (Ticagrelor N=12, 
Clopidogrel N=11). Median time of thrombolysis to Hour 0 was 16.9(10.2-21.9) hours. The majority of patients (78.3%) received tenecteplace and 
the rest of them (21.7%) reteplace. There were no differences in baseline and clinical characteristics between groups. The primary endpoint was 
significantly lower for ticagrelor compared to high clopidogrel (79.1 PRU, 95%CIs 47.8-110.5 vs 241.2 PRU, 95%CIs 208.2-274.2, p<0.001). PR at 
Hour 24 and pre-discharge was also significantly lower for ticagrelor compared to clopidogrel (32.1 PRU, 95%CIs -3.6 to 67.8 vs 171.1 PRU, 95%CIs 
133.6-208.6 and 20.7 PRU, 95%CIs -7.2 to 48.7 vs 170.6 PRU, 95%CIs 141.3-200.0 respectively, p<0.001 for both). HPR rates at Hour 2 and 24 
were significantly lower for ticagrelor compared to high clopidogrel regimen (8.3% vs 90.9%, p<0.001 and 0% vs 45.5%, p=0.01 respectively).
Conclusions: STEMI patients subjected to thrombolysis present high HPR rate under standard clopidogrel therapy. Ticagrelor offers superior 
antiplatelet action and effectively treats HPR compared to high clopidogrel therapy.
